The new no blog thing was a joke. I don't actually believe the blogs are designed to attract new money into IPIX.
The paucity of Aspire tapping, of course, is directly related to no new trials and the winding down/completion of current trials. Hopefully Leo Pharmaceutical realizes he can't start another new trial on Aspire funding.
On the other hand, the penultimate page of the January Corp Overview, lists: Anchor Each Drug Candidate in Additional Trials to Further Provide Favorable Return-On-Investment. That is under Strategic Direction. By the way, I thought IPIX drugs were already anchored?
So who knows what Leo Pharmaceutical is capable of.
News 
Market Data 
Discover 
